You are here:

April 2015

22 April 2015

Laboratory studies have shown two treatments currently used to treat skin conditions may have the potential to be developed into therapies to repair myelin in people with MS. However, this is very early research in animals and human cells, so the press coverage reporting the treatments as a 'cure', or 'reversing' or 'stopping' MS is somewhat premature.

02 April 2015

Results of the analysis of the 6 year data of the Department of Health (DH) MS Risk-sharing Scheme (RSS), published in the Lancet Neurology today, show that the disease modifying drugs Avonex, Betaferon, Copaxone and Rebif are cost effective and are clinically effective in reducing the progression of the disease in people with relapsing remitting multiple sclerosis (MS).